Interpace Diagnostics Group Inc (NASDAQ:IDXG)

0.8982
Delayed Data
As of 3:24pm ET
 -0.0117 / -1.29%
Today’s Change
0.72
Today|||52-Week Range
3.20
-11.94%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$29.0M

Company Description

Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Contact Information

Interpace Diagnostics Group, Inc.
Morris Corporate Center 1
Parsippany New Jersey 07054
P:(855) 776-6419
Investor Relations:

Employees

Shareholders

Mutual fund holders3.01%
Other institutional10.09%
Individual stakeholders0.60%

Top Executives

Jack E. StoverPresident, Chief Executive Officer & Director
Glenn GershonSenior Vice President-Operations
James EarlyChief Financial Officer. Secretary & Treasurer
Sydney D. FinkelsteinChief Scientific Officer
Sara A. JacksonVice President-Clinical Development